Introduction
In¯ammatory bowel disease comprises two chronic conditions, ulcerative colitis and Crohn's disease, the etiology of which is unknown. Ashkenazi Jews are proportionally over represented in the IBD population (Roth et al., 1989; Zlotogora et al., 1991) . Ulcerative colitis aects only the large bowel, while Crohn's disease may aect any portion of the alimentary tract. The most serious long-term complication of both diseases is adenocarcinoma of the intestine: for example, the risk of colorectal cancer is increased 10 ± 20-fold in patients with extensive, longstanding ulcerative colitis and Crohn's colitis (Ekbom et al., 1992; Harpaz and Talbot, 1996; Nugent et al., 1991) .
The adenomatous polyposis coli (APC) gene is the gatekeeper gene for sporadic colorectal carcinogenesis. Patients with germline mutations in this gene develop the disease familial adenomatous polyposis (FAP), while the majority of patients with sporadic colorectal cancer carry somatic mutations of APC in their tumors (Cho and Vogelstein, 1992; Smith et al., 1993) . Recently, a novel type of sequence alteration in APC was described which consists of a T to A transversion within codon 1307 of this gene, leading to the substitution of lysine for isoleucine (Laken et al., 1997) . This relatively benign missense mutation is not known to appreciably alter APC protein function. Rather, it creates a microsatellite tract consisting of eight deoxyadenines (A's) within the coding region of APC. Such coding region microsatellites are known to be prone to mutation. In fact, patients inheriting this variant sequence form of APC are at a 2 ± 4-fold increased risk of developing colon cancer. Approximately half of colorectal tumors that develop in patients who carry this isoform have suered a secondary`hit' on the allele carrying the isoform, resulting in expansion or contraction of the newly created microsatellite tract. These secondary mutations result in frameshift mutations which inactivate APC (Laken et al., 1997) .
The I1307K sequence has been reported to occur in 6.1 ± 7.9% of Ashkenazi Jewish patients in the United States (Abrahamson et al., 1998; Laken et al., 1997) . A very large proportion of IBD patients are Ashkenazi Jews, and IBD aecting the large bowel predisposes to colorectal carcinoma. We therefore sought to determine whether some of this increased risk could be attributed to a high germline prevalence of I1307K in IBD patients.
Results
Of 267 patients with in¯ammatory bowel disease, only two (0.7%) showed the I1307K sequence variant of APC in their germline DNA (Figures 1 and 2) . Both of these patients were heterozygous for I1307K, and both were Jews. We randomly queried 59 patients to determine their ethnicity: 30 of these patients stated that they were Jewish. Therefore, we estimated that of the 267 IBD patients, 30/596267 or approximately 136
were Jews, yielding a calculated I1307K frequency of 2/ 136 or 1.47% in this subgroup. Both patients were heterozygous for the I1307K sequence ( Figure 2) . Moreover, 43 of the IBD patients had cancer or dysplasia. However, none of these 43 patients carried the I1307K mutation in their germline DNA. In addition, among 67 patients with esophageal cancer, 53 patients with gastric cancer (13 MSI-H, 44 MSInegative), and ten patients with sporadic non-IBD colon cancer (all MSI-H), none harbored the I1307K sequence variant (data not shown). MSI-H was de®ned as microsatellite instability (MSI) in 430% of microsatellite loci examined, whereas MSI-L connoted MSI in 30% or fewer loci, and MSI-negative referred to MSI in none of the loci tested.
Tests of statistical signi®cance suggested that our observed rate of I1307K among Jews diered from the expected rate, which ranges from 6 ± 8% in published literature (Abrahamson et al., 1998; Laken et al., 1997; Lothe et al., 1998; Petrukhin et al., 1997) . We calculated the probability of observing two or fewer mutations among 136 samples under the hypothesis that the number observed is binomial, with a probability of mutation equal to 6%. This probability was found to be 0.01 (one-sided P-value). Doubling this probability yielded a two-sided P-value of 0.02. Thus, the proportion with I1307K was signi®cantly dierent from 6% (P=0.02). These calculations were made using a hand calculator.
Discussion
IBD comprises two premalignant idiopathic chronic in¯ammatory bowel diseases, ulcerative colitis and Crohn's disease. The reason for the predilection to intestinal cancer that accompanies these two diseases is not known. Chronic in¯ammatory states per se may predispose to carcinogenesis, as a strong association between in¯ammation and cancer has been established at other organ sites (Asaka et al., 1997; Lowenfels et al., 1993) . However, some of the increased cancer risk seen in IBD patients may also be hereditary. Since the I1307K sequence alteration occurs in germline DNA, and since it appears to predispose to colon cancer development, we sought to determine whether part of the cancer risk associated with IBD could be attributed to this sequence alteration. The lower prevalence of I1307K among Jewish patients with IBD (1.5%) was a surprising ®nding, since it con¯icts with prior studies reporting a high frequency of I1307K in Ashkenazi Jews with colorectal and ovarian cancer (Abrahamson et al., 1998; Laken et al., 1997; Lothe et al., 1998) . Furthermore, data supporting an increased risk of colon cancer in Ashkenazi Jews has been limited. An international cancer database showed that the cumulative incidence of colon cancer to age 74 among Jews born in Europe or North America (most of whom are Ashkenazi) is 3.6% for men and 2.7% for women. This contrasts only slightly with comparative ®gures of 3.3% for all men and 2.3% for all women in North America (IARC Cancer Incidence in Five Continents, Vol. 7 (1997) . IARC Publications: Lyon, France). Moreover, the initially reported I1307K prevalence rate among Ashkenazi Jews has varied in subsequent studies, for example in Jewish families with ovarian and colon cancer, none of whom carried the I1307K variant (Lothe et al., 1998; Petrukhin et al., 1997) .
These ®ndings suggest that the I1307K sequence variant is relatively rare in the Jewish IBD patient population, as well as in non-Jewish IBD patients and patients with sporadic gastric or esophageal cancer. Therefore, I1307K is unlikely to contribute significantly to the increased colorectal cancer risk associated with IBD. Larger surveys of Jewish populations are needed in order to determine the precise prevalence of and relative cancer risk conferred by this sequence variant.
Materials and methods
Genomic DNA was extracted from paran-embedded blocks of intestinal biopsies from patients with in¯ammatory bowel disease and patients with ulcerative colitis, or from frozen non-tumor tissues of patients with esophageal, gastric and colon cancers by standard methods. The region surrounding the I1307 sequence variant was PCR-ampli®ed using primers 5'-CCCTGCAGTCTGCTGGATTTGG-3' and 5'-TGTGTA- Figure 1 Autoradiograph of dideoxy-A sequencing screening assay. Lanes 1 ± 9 represent dideoxy-A termination reactions from PCR products ampli®ed from the codon 1307 region of APC in nine in¯ammatory bowel disease (IBD) patients. Lane 2 displays a mutation (AAATAAAA to AAAAAAAA; arrow) Figure 2 Direct sequencing of PCR products ampli®ed from the codon 1307 region of APC. Lanes 1 and 2, IBD patients with wild-type sequence; lane 3, positive control from Ashkenazi colon cancer patient; lanes 4 and 5, two IBD patients heterozygous for the AAATAAAA to AAAAAAAA mutation (arrow). Mutant signal (lanes`A' in samples 4 and 5) is weaker than wild-type signal (lanes`T') at the same locus (arrow) probably due to relative instability of the mutant RNA species GAAGATACTCCAATATG-3' (230-bp PCR product) at 528C for 2 min, 728C for 2 min, 35 cycles. The PCR products were directly sequenced using primer 5'-AT-CATCTTTGTCATCAGCTGAA-3' by the dideoxy-chain termination method (USB, Sequenase PCR sequencing kit. Cat# 70170). Dideoxy-A termination reactions were electrophoresed adjacent to each other on denaturing polyacrylamide gels as a ®rst screen. Samples containing a mutant`A' were subjected to reampli®cation and complete sequencing of all four nucleotides (G, A, T and C). A positive control DNA from an Ashkenazi Jewish colorectal cancer patient harboring the I1307K mutation (obtained from Steven J Laken, Johns Hopkins Oncology Center, Baltimore, MD, USA) was included in each analysis. Autoradiographic ®lms made from dried gels were examined by eye for alterations in the AAATAAA locus surrounding codon 1307 of APC.
Abbreviations MSI-H, microsatellite instability-high; MSI-L, microsatellite instability-low; MSI-negative, microsatellite instabilitynegative.
Note added in proof A recent study by Rozen et al. (1999) found that I1307K occurred in 1.6% of 188 Jews of non-European descent. Thus, a possible explanation for our low I1307K frequency is that many of our Jewish IBD patients were non-European.
